share_log

智翔金泰(688443.SH):GR2001注射液启动III期临床试验

Zhixiang Jintai (688443.SH): GR2001 injection launched Phase III clinical trial.

Gelonghui Finance ·  Aug 14 05:32

On August 14th, Gelunhui reported that Zhixiang Jintai (688443.SH) had completed communication with the Center for Drug Evaluation of the National Medical Products Administration (CDE) EOP2 (Phase II clinical trial completed/Phase III clinical trial started) on the conduct of a randomized, double-blind, tetanus immunoglobulin-controlled, multicenter Phase III clinical trial of the efficacy and safety of the evaluation of muscle injection GR2001 injection in suspected tetanus exposed persons, and the company will formally launch the Phase III clinical trial.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment